American Society of Hirudotherapy

Trigger Finger (Stenosing Tenosynovitis)

Investigational use for stenosing tenosynovitis of the digital flexor pulleys; evidence limited to a single Ayurvedic case report.

Tier C — InvestigationalInvestigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Last Updated: November 17, 2026 · ASH Editorial · based on the books

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for trigger finger. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is investigational.
What evidence exists?
Tier C (investigational). Only one single-patient case study of leech therapy for trigger finger was identified, and it combined leeches with other Ayurvedic treatments; no randomized controlled trials were identified. Evidence-based first-line therapy is observation with activity modification and splinting for mild cases, intra-tendon-sheath corticosteroid injection (highest non-surgical evidence; about 60 percent successful at 1 year), and percutaneous or open A1-pulley release for refractory cases. Hand-surgery outcomes are excellent and durable.
Main risks
  • Bleeding from bite sites for 6 to 24 hours after detachment
  • Bruising and tenderness over the palm for 5 to 10 days
  • Local skin infection or, rarely, Aeromonas infection
  • Allergic reaction to leech saliva (uncommon)
  • Temporary worsening of finger triggering or pain for 1 to 3 days
  • Damage to the digital neurovascular bundle if placement is improperly midline
  • Small permanent scars at bite sites on a visible hand surface
  • Delay or replacement of an effective corticosteroid injection or A1-pulley release
Who should not consider this
  • Patients with locked finger requiring urgent release
  • Patients within 4 weeks of a local corticosteroid injection
  • Patients with active palm infection or paronychia
  • Patients with diabetes-related tenosynovitis affecting multiple digits (consider systemic management)
  • Patients on anticoagulants, with hemophilia, or with anemia
  • Patients who have not tried evidence-based corticosteroid injection
  • Patients with diabetic neuropathy of the hand
  • Patients who have not been offered A1 pulley release surgery
What to ask your clinician
  • Has my trigger finger been confirmed (A1 pulley stenosing tenosynovitis)?
  • Have I tried splinting and at least one intra-tendon-sheath corticosteroid injection?
  • If injection fails, am I a candidate for percutaneous or open A1-pulley release?
  • Do I have diabetes (which worsens response to injection)?
  • What evidence supports leech therapy specifically for trigger finger?
  • Where exactly will leeches be placed — clearly off the digital neurovascular bundle?
  • What is the practitioner's experience and Aeromonas-prevention plan?
  • Are leeches from an FDA-registered supplier and used only once?
When to seek urgent care
  • A finger locked in flexion that you cannot release
  • Sudden severe finger pain, swelling, or inability to move
  • Spreading redness, warmth, pus, or red streaks on the hand (cellulitis or flexor tenosynovitis is a surgical emergency)
  • Bleeding from a bite site lasting more than 24 to 48 hours
  • Fever above 38.0 C / 100.4 F or chills
  • Numbness or coldness in the finger
  • Hives, throat tightness, or breathing difficulty

What this does NOT mean

  • This is not FDA-cleared for trigger finger.
  • A single case report does NOT establish efficacy versus corticosteroid injection or A1-pulley release.
  • Mechanism rationale (anti-inflammation at A1 pulley) does NOT establish clinical efficacy.
  • Leech therapy is not a substitute for a well-placed corticosteroid injection or hand-surgical release.
  • A locked digit needing release should NOT be deferred for complementary therapy.

Clinical Profile

Category
Musculoskeletal
ICD-10
M65.30, M65.311, M65.312, M65.321, M65.322
Safety tier
Low

Evidence Summary

No controlled clinical trial or case series of leech therapy for trigger finger (stenosing tenosynovitis) was identified in PubMed, Europe PMC, Crossref or Russian- and German-language searches. The only human report found is a single-patient Ayurvedic case study (Pashte and Tiwari 2020) in which leeches were combined with medicated enemas and hand steam therapy, so there is no reliable evidence that leech therapy resolves triggering. Any proposed mechanism (anti-inflammatory salivary peptides reducing flexor tenosynovial swelling at the A1 pulley) is speculative and unproven. Conventional management — corticosteroid injection, and percutaneous or open A1 pulley release for refractory cases — remains the standard. ASH position: any use of leech therapy for trigger finger is investigational and supported only by a single case report.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)

Contraindications

  • Hemophilia or another bleeding disorder
  • Taking anticoagulants (blood thinners such as warfarin or heparin)
  • Anemia or suppressed blood formation
  • Low blood pressure, shock, collapse or fainting
  • Severe wasting (cachexia)
  • Intolerance of leeches or a history of severe allergic reactions
  • Pregnancy
  • Stomach or duodenal ulcer, erosive gastritis
  • Acute infectious disease or high fever
  • Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
  • Drinking alcohol at the time of treatment
  • No consent from the patient
  • Active local infection
  • Recent (<4 weeks) local corticosteroid injection

Related Conditions

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.